New cancer drug WTX-330 shows promise in early human trial

NCT ID NCT05678998

Completed Disease control Sponsor: Werewolf Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called WTX-330 in 25 adults with advanced solid tumors or lymphoma that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study is now complete, and results will help guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Emory Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States
Facility Name: Roswell Park Comprehensive Cancer Care

Buffalo, New York, 14203, United States
HonorHealth

Scottsdale, Arizona, 85258, United States
Indiana University

Indianapolis, Indiana, 46202, United States
Mass General Hospital

Boston, Massachusetts, 02114, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
Northwestern University

Chicago, Illinois, 60611, United States
Providence Cancer Institute Franz Clinic

Portland, Oregon, 97213, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.